{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:21:55Z","timestamp":1793362915264,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["721236"],"award-info":[{"award-number":["721236"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["PEJD-2017-PRE\/BMD-|4164"],"award-info":[{"award-number":["PEJD-2017-PRE\/BMD-|4164"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinthera.2019.10.009","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:45:54Z","timestamp":1575506754000},"page":"2558-2570.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Manuel","family":"Garc\u00eda-Ferrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Wojnicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.10.009_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib5","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMe1004430","article-title":"Even better kinase inhibitors for chronic myeloid leukemia","volume":"363","author":"Sawyers","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.clinthera.2019.10.009_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620717719851","article-title":"Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update","volume":"8","author":"Eskazan","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2016.04.005","article-title":"Optimizing the use of TKIs in the management of chronic myelogenous leukemia","volume":"16","author":"Ruiz-Cordell","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2019.10.009_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib11","article-title":"Triazole antifungal therapeutic drug monitoring","volume":"vol.12","author":"Lewis","year":"2015"},{"key":"10.1016\/j.clinthera.2019.10.009_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.18773\/austprescr.2008.025","article-title":"Therapeutic drug monitoring: which drugs, why, when and how to do it","volume":"31","author":"Ghiculescu","year":"2008","journal-title":"Aust Prescr"},{"key":"10.1016\/j.clinthera.2019.10.009_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2019.10.009_bib14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sinica"},{"key":"10.1016\/j.clinthera.2019.10.009_bib15","first-page":"61","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","volume":"10","author":"Takano","year":"2017","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.clinthera.2019.10.009_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-5-23","article-title":"Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation","volume":"5","author":"Takahashi","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib17","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib19","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2013response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00277-011-1394-x","article-title":"Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting","volume":"91","author":"Faber","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib21","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.10.009_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FTD.0000000000000406","article-title":"Simultaneous determination of imatinib, dasatinib, and nilotinib by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring","volume":"39","author":"Wojnicz","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2019.10.009_bib25","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2019.10.009_bib26","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Therapeutic drug monitoring in CML patients on imatinib","volume":"110","author":"Blasdel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2019.10.009_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00280-015-2905-6","article-title":"A\u00a0study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients","volume":"76","author":"Francis","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00280-014-2473-1","article-title":"Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia","volume":"74","author":"Golabchifar","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial","volume":"74","author":"Gotta","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","article-title":"Large-scale imatinib dose\u2013concentration\u2013effect study in CML patients under routine care conditions","volume":"38","author":"Gotta","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2019.10.009_bib33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","article-title":"Trough plasma concentration of imatinib reflects BCR\u2013ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study","volume":"101","author":"Ishikawa","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2019.10.009_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","article-title":"Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia","volume":"89","author":"Kawaguchi","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hon.2005","article-title":"Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC","volume":"30","author":"Koren-Michowitz","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib36","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1349-7006.2012.02253.x","article-title":"Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study","volume":"103","author":"Ohnishi","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2019.10.009_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2016.04.003","article-title":"Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study","volume":"16","author":"Ostojic","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2019.10.009_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood.V126.23.133.133","article-title":"Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results of the Randomized OPTIM Imatinib Study","volume":"126","author":"Rousselot","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.10.009_bib41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/0973-1482.136583","article-title":"Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase","volume":"10","author":"Sharma","year":"2014","journal-title":"J\u00a0Can Res Ther"},{"key":"10.1016\/j.clinthera.2019.10.009_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/FTD.0000000000000268","article-title":"In\u00a0Vivo cytochrome P450 3A isoenzyme activity and pharmacokinetics of imatinib in relation to therapeutic outcome in patients with chronic myeloid leukemia","volume":"38","author":"Skoglund","year":"2016","journal-title":"Drug Monit"},{"key":"10.1016\/j.clinthera.2019.10.009_bib44","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3109\/10428194.2011.563885","article-title":"Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia","volume":"52","author":"Sohn","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2019.10.009_bib45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J\u00a0Hum Genet"},{"key":"10.1016\/j.clinthera.2019.10.009_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.10.009_bib47","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clinbiochem.2016.12.006","article-title":"The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study","volume":"50","author":"Van Obbergh","year":"2017","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinthera.2019.10.009_bib48","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2019.10.009_bib49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12185-011-0838-3","article-title":"Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia","volume":"93","author":"Yoshida","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 *6, *27, and *28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2019.10.009_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ajh.23125","article-title":"Pharmacokinetics of nilotinib in imatinib-resistant\/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure","volume":"87","author":"Onaka","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2050-7771-2-6","article-title":"Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib","volume":"2","author":"Takahashi","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.clinthera.2019.10.009_bib56","article-title":"Effect of plasma trough concentration of nilotinib and polymorphisms of drug transporter genes on the frequency of adverse events in chronic phase of chronic myeloid leukemia: sTAT 1 and STAT2 trials","author":"Takahashi","year":"2017"},{"key":"10.1016\/j.clinthera.2019.10.009_bib57","first-page":"9","article-title":"Dasatinib daily dose optimization based on therapeutic drug monitoring resulted in reduced risk of pleural effusions and high molecular response rates","volume":"29","author":"Bouchet","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia","volume":"72","author":"Ishida","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2019.10.009_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","article-title":"High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-Systematic review and meta-analysis","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2019.10.009_bib61","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:35Z","timestamp":1758963095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0149291819305053"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}